Search

Your search keyword '"Hirose, Mizuo"' showing total 15 results
Start Over Author "Hirose, Mizuo"
15 results on '"Hirose, Mizuo"'

5. Phase III Clinical Trials Comparing the Immunogenicity and Safety of the Vero Cell-Derived Japanese Encephalitis Vaccine Encevac with Those of Mouse Brain-Derived Vaccine by Using the Beijing-1 Strain

Author

Miyazaki, Chiaki, primary, Okada, Kenji, additional, Ozaki, Takao, additional, Hirose, Mizuo, additional, Iribe, Kaneshige, additional, Yokote, Hiroyuki, additional, Ishikawa, Yuji, additional, Togashi, Takehiro, additional, and Ueda, Kohji, additional

Published
2013
Full Text
View/download PDF

7. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin

Author

KIMURA, MIKIO, primary, KUNO-SAKAI, HARUMI, additional, KAMIYA, HITOSHI, additional, UEDA, KOHJI, additional, ISOMURA, SHIN, additional, KOIKE, MICHIO, additional, KATO, TATSUO, additional, OZAKI, TAKAO, additional, HIROSE, MIZUO, additional, and EGAMI, TSUNEYOSHI, additional

Published
1995
Full Text
View/download PDF

9. Primary Reninism With Renal Hamartomatous Alteration

Author

Hirose, Mizuo, Arakawa, Kikuo, Kikuchi, Masahiro, Kawasaki, Terukazu, Omoto, Tetsuo, Kato, Hirohisa, and Nagayama, Tokuro

Abstract

This is the eighth case of primary reninism so far reported, but it is unusual in that the patient was very young (10 years of age) and the tumor was very small (0.2×0.15 cm), without delineation, yet cure was effected quickly (in five months). The boy, first admitted with malignant hypertension, was thought to have a juxtaglomerular (JG) cell tumor because of typical findings for it: hypertension, hypokalemia, hyperaldosteronism, and unilaterally (right) elevated renal vein plasma renin activity (PRA), with no disparity or abnormality on nephrogram or renal angiogram. Right nephrectomy resulted in a prompt cure and return of PRA to normal levels, but no delineated tumor was found in the excised right kidney. Reexamination showed an extremely small (0.2×0.15 cm) circumscribed nodular lesion in the cortex, which consisted of a group of peculiar cells whose characteristics coincided with neither hemangiopericytoma nor Wilms tumor. Several explanations are possible for the histological findings.(JAMA 230:1288-1292, 1974)

Published
1974
Full Text
View/download PDF

15. Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.

Author

Miyazaki C, Okada K, Ozaki T, Hirose M, Iribe K, Yokote H, Ishikawa Y, Togashi T, and Ueda K

Subjects
Animals, Child, Child, Preschool, Humans, Infant, Japanese Encephalitis Vaccines administration & dosage, Japanese Encephalitis Vaccines isolation & purification, Mice, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated adverse effects, Vaccines, Inactivated immunology, Vaccines, Inactivated isolation & purification, Vero Cells, Encephalitis, Japanese prevention & control, Japanese Encephalitis Vaccines adverse effects, Japanese Encephalitis Vaccines immunology
Abstract

The immunogenicity and safety of an inactivated cell culture Japanese encephalitis vaccine (CC-JEV) were compared with those of an inactivated mouse brain-derived Japanese encephalitis vaccine (MB-JEV) in phase III clinical multicenter trials conducted in children. The vaccines contain the same Japanese encephalitis virus strain, the Beijing-1 strain. Two independent clinical trials (trials 1 and 2) were conducted. Trial 1 was conducted in 468 healthy children. Each subject was injected with 17 μg per dose of either CC-JEV or MB-JEV, and the immunogenicity and safety of the vaccines were investigated. Trial 1 showed that CC-JEV was more immunogenic and reactive than MB-JEV at the same dose. Therefore, to adjust the immunogenicity of CC-JEV to that of MB-JEV, a vaccine that has had a good track record regarding its efficacy for a long time, trial 2 was conducted in 484 healthy children. To improve the stability, CC-JEV was converted from a liquid type to a freeze-dried type of vaccine. Each subject was injected subcutaneously with either 4 μg per dose of CC-JEV, 8 μg per dose of CC-JEV, or 17 μg per dose of MB-JEV twice, at an interval of 2 to 4 weeks, followed by an additional booster immunization 1 to 15 months after the primary immunization. Based on the results of trial 2, 4 μg per dose of the freeze-dried CC-JEV (under the label Encevac) was selected as a substitute for the MB-JEV. Encevac was approved and launched in 2011 and has since been in use as a 2nd-generation Japanese encephalitis vaccine in Japan. (These studies have been registered at the JapicCTI under registration no. JapicCTI-132063 and JapicCTI-080586 for trials 1 and 2, respectively).

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results